Home Tags Brentuximab Vedotin

Tag: Brentuximab Vedotin

Supplemental BLA for Brentuximab Vedotin in Post-Transplant Hodgkin Lymphoma Patients at...

Based on positive data from the Phase III AETHERA trial (SGN35-005; NCT01100502) of brentuximab vedotin (Adcetris®; Seattle Genetics, Inc/Takeda Oncology) as consolidation therapy immediately following...

Four-Year Survival Data from Brentuximab Vedotin Trial in Relapsed or Refractory...

Four-year overall survival (OS) data from the brentuximab vedotin (Adcetris®; Seattle Genetics) pivotal Phase II clinical trial in relapsed or refractory systemic anaplastic large cell...

Harnessing the Power of Three: Advancing Antibody-Drug Conjugates from Laboratory to...

Antibody-drug conjugates or ADCs are creating much excitement among life science professionals, medical/clinical research scientists and pharmaceutical specialists. At the same time, oncologists and hematologists are eager to welcome new treatment options in the ongoing war against cancer. This article reviews some of the advances made in the development of ADCs.

From the Editors: Welcome to a New Publication – ADC Review/Journal...

Welcome to ADC Review, Journal of Antibody-Drug Conjugates, a new online, peer-reviewed, open-access hybrid publication for those involved in the ongoing--and exciting--development of antibody-drug...